Antitumour Efficacy of Two Paclitaxel Formulations for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in an In Vivo Rat Model

被引:12
作者
Bouquet, Wim [1 ]
Deleye, Steven [2 ]
Staelens, Steven [2 ,3 ]
De Smet, Lieselotte [1 ]
Van Damme, Nancy [4 ]
Debergh, Isabelle [5 ]
Ceelen, Wim P. [5 ]
De Vos, Filip [6 ]
Remon, Jean Paul [1 ]
Vervaet, Chris [1 ]
机构
[1] Univ Ghent, Pharmaceut Technol Lab, B-9000 Ghent, Belgium
[2] Ghent Univ IBBT, Ghent, Belgium
[3] Univ Antwerp, Mol Imaging Ctr Antwerp, B-2020 Antwerp, Belgium
[4] Ghent Univ Hosp, Dept Gastroenterol, B-9000 Ghent, Belgium
[5] Ghent Univ Hosp, Dept Gastrointestinal Surg, B-9000 Ghent, Belgium
[6] Univ Ghent, Lab Radiopharm, B-9000 Ghent, Belgium
关键词
hyperthermic intraperitoneal chemotherapy; paclitaxel; tumour growth delay; beta-cyclodextrin; PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; OVARIAN-CANCER; COLORECTAL-CANCER; CREMOPHOR EL; CYCLODEXTRIN COMPLEXES; SYSTEMIC CHEMOTHERAPY; THERMAL ENHANCEMENT; RANDOMIZED-TRIAL; DRUG-DELIVERY;
D O I
10.1007/s11095-011-0401-1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To evaluate the tumour growth delay of a peritoneal carcinomatosis (PC) of colorectal origin after intraperitoneal chemotherapy with paclitaxel/randomly-methylated-beta-cyclodextrin (Pac/RAME-beta-CD) versus TaxolA (R) at normo- and hyperthermic conditions in rats. Hyperthermic intraperitoneal chemotherapy (HIPEC) was performed 7 days post implantation of the tumour with both formulations at a Pac concentration of 0.24 mg/ml. Tumour evaluation was performed via positron emission tomography (PET) and magnetic resonance imaging (MRI) imaging, measuring tumour activity and tumour volume, respectively. Scans were taken at 2 and 7 days post treatment. PET and MRI data showed a significant reduction in tumour activity and tumour volume for rats treated with Pac/RAME-beta-CD (at normo- and hyperthermic conditions), compared to the control group. Treatment with TaxolA (R) did not result in a significant reduction of tumour activity and tumour volume. No significant differences between the normo- and hyperthermic conditions were observed for both formulations, indicating that hyperthermia and paclitaxel were not synergistic despite the direct cytotoxic effect of hyperthermia. Monitoring tumour growth via PET and MRI indicated that Pac/RAME-beta-CD inclusion complexes had a significantly higher efficacy compared to TaxolA (R) in a rat model for peritoneal carcinomatosis.
引用
收藏
页码:1653 / 1660
页数:8
相关论文
共 29 条
[1]   Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery [J].
Bae, Jeong Hoon ;
Lee, Joon Mo ;
Ryu, Ki Sung ;
Lee, Yong Seok ;
Park, Yong Gyu ;
Hur, Soo Young ;
Ahn, Woong Shik ;
Namkoong, Seong Eun .
GYNECOLOGIC ONCOLOGY, 2007, 106 (01) :193-200
[2]   Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer [J].
Bijelic, L. ;
Jonson, A. ;
Sugarbaker, P. H. .
ANNALS OF ONCOLOGY, 2007, 18 (12) :1943-1950
[3]   In vivo Toxicity and Bioavailability of Taxol® and a Paclitaxel/β-Cyclodextrin Formulation in a Rat Model During HIPEC [J].
Bouquet, W. ;
Ceelen, W. ;
Adriaens, E. ;
Almeida, A. ;
Quinten, T. ;
De Vos, F. ;
Pattyn, P. ;
Peeters, M. ;
Remon, J. P. ;
Vervaet, C. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (09) :2510-2517
[4]   In vitro cytotoxicity of paclitaxel/β-cyclodextrin complexes for HIPEC [J].
Bouquet, W. ;
Boterberg, T. ;
Ceelen, W. ;
Pattyn, P. ;
Peeters, M. ;
Bracke, M. ;
Remon, J. P. ;
Vervaet, C. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 367 (1-2) :148-154
[5]   Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion -: Formulation and stability [J].
Bouquet, Wim ;
Ceelen, Wirn ;
Fritzinger, Bernd ;
Pattyn, Piet ;
Peeters, Marc ;
Remon, Jean Paul ;
Vervaet, Chris .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 66 (03) :391-397
[6]   Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment [J].
Ceelen, Wim P. ;
Bracke, Marc E. .
LANCET ONCOLOGY, 2009, 10 (01) :72-79
[7]   Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma [J].
Cividalli, A ;
Cruciani, G ;
Livdi, E ;
Pasqualetti, P ;
Danesi, DT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (02) :407-412
[8]   Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside [J].
de Bree, Eelco ;
Theodoropoulos, Panayiotis A. ;
Rosing, Hilde ;
Michalakis, John ;
Romanos, John ;
Beijnen, Jos H. ;
Tsiftsis, Dimitris D. .
CANCER TREATMENT REVIEWS, 2006, 32 (06) :471-482
[9]   Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study [J].
Debree, Eelco ;
Rosing, Hilde ;
Filis, Dimitris ;
Romanos, John ;
Melisssourgaki, Maria ;
Daskalakis, Markos ;
Pilatou, Maria ;
Sanidas, Elias ;
Taflampas, Panagiotis ;
Kalbakis, Konstantinos ;
Beijnen, Jos H. ;
Tsiftsis, Dimitris D. .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (04) :1183-1192
[10]   Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement [J].
Esquivel, J. ;
Sticca, R. ;
Sugarbaker, P. ;
Levine, E. ;
Yan, T. D. ;
Alexander, R. ;
Baratti, D. ;
Bartlett, D. ;
Barone, R. ;
Barrios, P. ;
Bieligk, S. ;
Bretcha-Boix, P. ;
Chang, C. K. ;
Chu, F. ;
Chu, Q. ;
Daniel, S. ;
deBree, E. ;
Deraco, M. ;
Dominguez-Parra, L. ;
Elias, D. ;
Flynn, R. ;
Foster, J. ;
Garofalo, A. ;
Gilly, F. N. ;
Glehen, O. ;
Gomez-Portilla, A. ;
Gonzalez-Bayon, L. ;
Gonzalez-Moreno, S. ;
Goodman, M. ;
Gushchin, V. ;
Hanna, N. ;
Hartmann, J. ;
Harrison, L. ;
Hoefer, R. ;
Kane, J. ;
Kecmanovic, D. ;
Kelley, S. ;
Kuhn, J. ;
LaMont, J. ;
Lange, J. ;
Li, B. ;
Loggie, B. ;
Mahteme, H. ;
Mann, G. ;
Martin, R. ;
Misih, R. A. ;
Moran, B. ;
Morris, D. ;
Onate-Ocana, L. ;
Petrelli, N. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) :128-133